Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Sleep Cycle AB in connection with the listing on Nasdaq Stockholm
Mandate

Vinge advises Sleep Cycle AB (publ) in connection with the listing on Nasdaq Stockholm

June 08, 2021 Capital Markets and Public M&A M&A Corporate Tax Intellectual Property Employment and Benefits

Vinge advises Sleep Cycle AB (publ) (“Sleep Cycle” or the “Company”) in connection with the listing on Nasdaq Stockholm. The offering circular was published on 28 May 2021 and the first day of trading on Nasdaq Stockholm was 8 June 2021.

The offering price was SEK 70 per share, corresponding to a market value of Sleep Cycle of approximately SEK 1.3bn. The offering comprised 4,870,171 shares, of which 1,428,571 are newly issued shares and 3,441,600 are existing shares.

Sleep Cycle is a market leading sleep tracking application with a mission to empower people to sleep better to improve global health. Sleep Cycle uses a patented AI-based audio technology to measure users’ sleep and provide personalized insights based on the Company’s sleep database. Sleep Cycle was founded in 2009 and is headquartered in Gothenburg, Sweden.

Vinge’s team mainly consisted of Jesper Schönbeck, Linnéa Sellström, Joel Magnusson and Lorin Arabi (Capital Markets and Public M&A), Matthias Pannier, Vilhelm Rondahl and Mikaela Falkner (M&A), Victor Ericsson, Henrik Wastenson and Jonathan Riddersholm (Corporate tax), Stojan Arnestål and Felizia Wiker (IP) and Ebba Svenburg (Employment and Benefits).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025